Up a level
Export as [feed] Atom [feed] RSS 1.0 [feed] RSS 2.0
Group by: Item Type | Date | No Grouping
Jump to: 2018 | 2016 | 2015
Number of items: 3.

2018

Moesges, R., Kasche, E. M., Raskopf, E., Singh, J., Sohlich, L., Astvatsatourov, A., Shah-Hosseini, K., Pirotton, S., Haazen, L., Durham, S. R., Legon, T., Zadoyan, G. and Shamji, M. H. (2018). A randomized, double-blind, placebo-controlled, dose-finding trial with Lolium perenne peptide immunotherapy. Allergy, 73 (4). S. 896 - 905. HOBOKEN: WILEY. ISSN 1398-9995

2016

Zadoyan, G., V, Allekotte, S., Shamji, M. H., Kasche, E. M., Singh, J., Astvatsatourov, A., Shah-Hosseini, K., Pirotton, S., Legon, T., Caplanusi, A., Durham, S. R. and Mosges, R. (2016). Immunological biomarker predict clinical effects in subcutaneous peptide allergen immunotherapy. Allergy, 71. S. 319 - 321. HOBOKEN: WILEY-BLACKWELL. ISSN 1398-9995

2015

Shamji, M. H., Kasche, E. M., Zadoyan, G., Astvatsourov, A., Durham, S. R., Pirotton, S., Legon, T. and Moesges, R. (2015). Hydrolyzed Lolium perenne peptide fragments administered subcutaneously to hay fever patients induce allergen-specific IgG(4) and blocking antibodies after two or more weeks of treatment. Allergy, 70. S. 631 - 633. HOBOKEN: WILEY-BLACKWELL. ISSN 1398-9995

This list was generated on Mon Sep 26 06:58:17 2022 CEST.